This exploratory analysis looked at patients with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv). The study included 144 patients receiving eplontersen and compared results to 60 historical patients who received placebo. Researchers tracked changes in amyloid protein levels, nerve function, and quality of life over time.
The results suggest that eplontersen significantly reduced serum transthyretin levels, with reductions ranging from about 71% to 85% compared to the historical placebo group. Patients taking the medication also showed maintained nerve function and improved quality of life scores, whereas the historical placebo group experienced worsening. Additionally, patients on eplontersen maintained their body weight, while the historical placebo group showed marked weight reduction.
Because this analysis used historical data for the control group, the findings are considered suggestive rather than definitive proof of benefit. The study was an exploratory analysis of a larger Phase 3 trial. While the results look promising for early-onset and late-onset disease, readers should note that these specific comparisons were not part of the original primary trial design. More data is needed to confirm these benefits in a direct head-to-head comparison.